Literature DB >> 16344312

Gemcitabine doublets in advanced pancreatic cancer: should we move on?

Caio Max Sao Pedro Rocha Lima, Aurea Maria Flores.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344312     DOI: 10.1200/JCO.2005.03.8315

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.

Authors:  Xiu-Wei Zhang; Yu-Xiang Ma; Yang Sun; Yu-Bo Cao; Qin Li; Chong-An Xu
Journal:  Target Oncol       Date:  2017-06       Impact factor: 4.493

2.  Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Authors:  Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2007-06-29       Impact factor: 3.199

3.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.

Authors:  A Sultana; C Tudur Smith; D Cunningham; N Starling; J P Neoptolemos; P Ghaneh
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.